These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 25184174)

  • 41. [Chronic hepatitis C drug therapy update].
    Ruano Camps R; Gallego Fernández C
    Farm Hosp; 2003; 27(6):371-85. PubMed ID: 14974883
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Costs of new treatments for hepatitis C infection.
    Green JB
    JAMA; 2014 Nov; 312(20):2168. PubMed ID: 25423229
    [No Abstract]   [Full Text] [Related]  

  • 43. Costs of new treatments for hepatitis C infection.
    Lopert R; Welch C
    JAMA; 2014 Nov; 312(20):2168. PubMed ID: 25423228
    [No Abstract]   [Full Text] [Related]  

  • 44. Hepatitis C Treatment in Prisons - Incarcerated People's Uncertain Right to Direct-Acting Antiviral Therapy.
    Daniels AM; Studdert DM
    N Engl J Med; 2020 Aug; 383(7):611-613. PubMed ID: 32786186
    [No Abstract]   [Full Text] [Related]  

  • 45. The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy.
    Backx M; Lewszuk A; White JR; Cole J; Sreedharan A; van Sanden S; Diels J; Lawson A; Neal KR; Wiselka MJ; Ito T; Irving WL
    J Viral Hepat; 2014 Mar; 21(3):208-15. PubMed ID: 24438682
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Costs of new treatments for hepatitis C infection--reply.
    Brennan TA; Shrank WH
    JAMA; 2014 Nov; 312(20):2168-9. PubMed ID: 25423230
    [No Abstract]   [Full Text] [Related]  

  • 47. Is hepatitis C virus eradication around the corner only 25 years after its discovery?
    Ippolito G; Capobianchi MR; Lanini S; Antonelli G
    Int J Antimicrob Agents; 2015 Feb; 45(2):111-2. PubMed ID: 25249016
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Medical resource utilisation and healthcare costs in patients with chronic hepatitis C viral infection and thrombocytopenia.
    Poordad F; Theodore D; Sullivan J; Grotzinger K
    J Med Econ; 2011; 14(2):194-206. PubMed ID: 21348807
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sovaldi ushers in wave of costly hepatitis C drugs.
    Manag Care; 2014 Jan; 23(1):51. PubMed ID: 24765752
    [No Abstract]   [Full Text] [Related]  

  • 50. Campaigners challenge patent applications for hepatitis C drug in five countries.
    Bagcchi S
    BMJ; 2015 Jun; 350():h2938. PubMed ID: 26032985
    [No Abstract]   [Full Text] [Related]  

  • 51. Adopting more systematic approaches to hepatitis C treatment in correctional facilities.
    Hammett TM
    Ann Intern Med; 2003 Feb; 138(3):235-6. PubMed ID: 12558365
    [No Abstract]   [Full Text] [Related]  

  • 52. Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection.
    Gordon SC; Pockros PJ; Terrault NA; Hoop RS; Buikema A; Nerenz D; Hamzeh FM
    Hepatology; 2012 Nov; 56(5):1651-60. PubMed ID: 22610658
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
    Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Costs of a guideline-based treatment of patients with chronic hepatitis C in Germany].
    Stahmeyer JT; Rossol S; Bert F; Abdelfattah M; Krauth C
    Z Gastroenterol; 2014 Sep; 52(9):1041-9. PubMed ID: 25075995
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hepatitis C therapy: is it really worth it?
    Johanson JF
    Am J Gastroenterol; 1999 May; 94(5):1412-3. PubMed ID: 10235231
    [No Abstract]   [Full Text] [Related]  

  • 56. Prisons face hep C-treatment funding crisis.
    Webster P
    CMAJ; 2016 Feb; 188(3):178-179. PubMed ID: 26783333
    [No Abstract]   [Full Text] [Related]  

  • 57. Towards hepatitis C eradication from the HIV-infected population.
    Barreiro P; Fernandez-Montero JV; de Mendoza C; Labarga P; Soriano V
    Antiviral Res; 2014 May; 105():1-7. PubMed ID: 24534673
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment of hepatitis C: momentum still needed.
    The Lancet Gastroenterology Hepatology
    Lancet Gastroenterol Hepatol; 2018 May; 3(5):289. PubMed ID: 29644967
    [No Abstract]   [Full Text] [Related]  

  • 59. [Hepatitis C: reimbursement extension].
    Zuercher C
    Rev Med Suisse; 2015 Aug; 11(482):1510. PubMed ID: 26449110
    [No Abstract]   [Full Text] [Related]  

  • 60. [The burden of viral hepatitis in the Russian Federation requires reducing its progression for the long term, including chronic hepatitis C)].
    Iushchuk ND; Znoĭko OO; Iakushechkina NA; Zyrianov SK; Shut'ko SA; Belyĭ PA; Kozina AN; Chapurin SA; Churilin IuIu; Lugovskikh EA
    Ter Arkh; 2013; 85(12):79-85. PubMed ID: 24640674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.